Emerging personalized treatment approaches for chronic urticari.
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC
The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency
October 13, 2023